Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology 1993-02-01

Trimethadione metabolism as a probe drug to estimate hepatic oxidizing capacity in rats.

E Tanaka, A Ishikawa, S Kobayashi, H Yasuhara, S Misawa, Y Kuroiwa

Index: Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. 104(2) , 205-7, (1993)

Full Text: HTML

Abstract

1. Trimethadione (TMO) has the properties required of probe drugs for the evaluation of hepatic oxidizing capacity in vivo. 2. TMO is demethylated to dimethadione (DMO), its only metabolite, in the liver after oral administration. 3. In rats with various types of hepatic intoxicated-, induced- and partially hepatectomized-rats, the serum DMO/TMO ratios, which were measured on blood samples obtained by a single collection 2 hr after oral administration of TMO, correlated well with the degree of hepatic damage or induction. 4. This finding suggests that TMO may be used as a probe drug in the rapid determination of the functional reserve mass of the liver as well as the hepatic oxidizing capacity.

Related Compounds

  • Trimethadione

Related Articles:

[Fetal trimethadione syndrome].

[Ryōikibetsu shōkōgun shirīzu (33) , 704, (2001)]

[Fetal trimethadione effects].

[Ryōikibetsu shōkōgun shirīzu (30 Pt 5) , 94-5, (2000)]

Trimethadione as a probe drug to estimate hepatic oxidizing capacity in humans.

1996-11-01

[Comp. Biochem. Physiol. C, Pharmacol. Toxicol. Endocrinol. 115(3) , 211-6, (1996)]

Zebrafish (Danio rerio) embryos as a model for testing proteratogens.

2011-03-15

[Toxicology 281(1-3) , 25-36, (2011)]

The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil.

2005-10-03

[Eur. J. Pharmacol. 521(1-3) , 79-85, (2005)]

More Articles...